olivLaw · European equity research
Meko Ab MEKO.ST
Sweden · Nasdaq Stockholm · ISIN SE0002110064 · Vertical: Listed companies from Sweden
At the close of 09 Nov 2026, Meko Ab (MEKO.ST) stock was 71.20 SEK (+0.92% on the day), with market capitalisation 4.0 bn SEK, P/E 111.3 on diluted EPS of 0.64 SEK over the last 12 months, dividend yield 5.48%, beta 0.52, 52-week range 63.50–79.35 SEK.
Data as of · Source: ESEF annual reports and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 58.7
- strong (55–70)
- Bollinger (20, 2)
- 68.40 – 71.33
- in the upper half of the band · %B 0.96 · band width 4.2%
- SMA 50 / 200
- 69.93 / 72.03
- mixed trend
- MACD (12, 26, 9)
- 0.36 / 0.10
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | EURO STOXX 50 | vs EURO STOXX 50 | Vertical median | |
|---|---|---|---|---|
| 1 month | +2.7% | +1.9% | +0.8 pp | — |
| 3 months | −6.0% | −3.8% | −2.3 pp | — |
| 6 months | −4.7% | +6.7% | −11.4 pp | — |
| Year to date | −2.3% | +8.5% | −10.9 pp | — |
| 1 year | −4.4% | +13.0% | −17.4 pp | −7.9% |
| 3 years | −30.7% | +49.9% | −80.5 pp | +12.9% |
| 5 years | −50.9% | +44.6% | −95.5 pp | — |
Price returns, dividends excluded.
Quarterly results
ESEF annual reports carry no quarters: the results are annual (below).
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Today's P/E sits at the 67 percentile of its own 3-quarter history (min 14.6, median 17.3, max 113.9; quarters with earnings only).
Fiscal years
| Fiscal year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 16.8 bn | 18.0 bn | 18.0 bn |
| Revenue YoY | unavailable | +7.7% | −0.2% |
| Net income | 419.0 m | 433.0 m | 36.0 m |
| Net income YoY | unavailable | +3.3% | −91.7% |
| Diluted EPS | 7.50 | 7.74 | 0.64 |
| Diluted EPS YoY | unavailable | +3.2% | −91.7% |
| net % | 2.5% | 2.4% | 0.2% |
| Free cash flow | 1.1 bn | 1.2 bn | 800.0 m |
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 566.0 m SEK
- Financial debt
- 3.5 bn SEK
- Net debt
- 2.9 bn SEK
- Equity
- 6.0 bn SEK
- Total assets
- 17.5 bn SEK
- Debt / equity
- 0.57x
- Current ratio
- 1.55x
- ROE
- 0.6%
- ROA
- 0.2%
- FCF margin
- 4.4%
Financial statements (source on every figure)
Revenue and net income (SEK)
Margins
Income statement · SEK
| Line | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|
| Revenue | 16.8 bn | 18.0 bn | 18.0 bn | esef· 26 Oct 2026verified |
| Operating income | 872.0 m | 902.0 m | 500.0 m | esef· 26 Oct 2026verified |
| Pre-tax income | 582.0 m | 627.0 m | 126.0 m | esef· 26 Oct 2026verified |
| Income tax | 132.0 m | 158.0 m | 65.0 m | esef· 26 Oct 2026verified |
| Net income | 419.0 m | 433.0 m | 36.0 m | esef· 26 Oct 2026verified |
| Diluted EPS | 7.50 | 7.74 | 0.64 | esef· 26 Oct 2026verified |
| Dividend per share | 3.70 | 3.90 | 3.90 | esef· 26 Oct 2026verified |
Balance sheet · SEK
| Line | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|
| Cash | 623.0 m | 607.0 m | 566.0 m | esef· 26 Oct 2026verified |
| Receivables | 1.5 bn | 1.5 bn | — | esef· 08 May 2025verified |
| Inventories | — | 5.1 bn | 5.0 bn | esef· 26 Oct 2026verified |
| Current assets | 7.5 bn | 8.2 bn | 8.1 bn | esef· 26 Oct 2026verified |
| Property, plant & equipment, net | 748.0 m | 802.0 m | 805.0 m | esef· 26 Oct 2026verified |
| Goodwill | 4.1 bn | 4.1 bn | 3.9 bn | esef· 26 Oct 2026verified |
| Total assets | 16.0 bn | 16.9 bn | 17.5 bn | esef· 26 Oct 2026verified |
| Short-term debt | 12.0 m | 10.0 m | — | esef· 08 May 2025verified |
| Long-term debt | 3.6 bn | 3.2 bn | 3.5 bn | esef· 26 Oct 2026verified |
| Current liabilities | 4.4 bn | 5.0 bn | 5.2 bn | esef· 26 Oct 2026verified |
| Equity | 6.2 bn | 6.6 bn | 6.0 bn | esef· 26 Oct 2026verified |
| Shares outstanding at year end | 55.9 m | 55.9 m | 56.3 m | esef· 26 Oct 2026derived |
Cash flow · SEK
| Line | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|
| Operating cash flow | 1.3 bn | 1.4 bn | 1.0 bn | esef· 26 Oct 2026verified |
| Capex | 155.0 m | 178.0 m | 213.0 m | esef· 26 Oct 2026verified |
| Free cash flow | 1.1 bn ≈ | 1.2 bn ≈ | 800.0 m ≈ | esef· 26 Oct 2026derived |
| Investing cash flow | 213.0 m | -112.0 m | -280.0 m | esef· 26 Oct 2026verified |
| Financing cash flow | -1.6 bn | -1.3 bn | -737.0 m | esef· 26 Oct 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- score weight coverage: 45.8% of at least 60%
A scoring methodology on indicators and valuation, not investment advice.
Closing price
09 Nov 2026Source: olivLaw, closing series
Market cap: 4.0 bn SEK
Key indicators
Coverage and freshness
Score by group
46% · Insufficient data
Estimated value range
unavailable — no valuation assumptions for the reporting currency
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
Assumptions (illustrative, editorial)
- Risk-free rate
- 6.5%
- Equity risk premium
- 6.0%
- Beta (default)
- 1.00
- Cost of equity
- 12.5%
- Terminal growth
- 3.0%
Factor scorecard
Insufficient data
Minimum-evidence gate: score weight coverage: 45.8% of at least 60%
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | 4.6% | 26 (vs peers) | 23% |
| Net margin · Quality | 0.2% | 22 (vs peers) | 14% |
| FCF conversion · Quality | 2,222.2% | 100 (on a fixed band) | 14% |
| Revenue CAGR 3Y · Growth | unavailable | unavailable | — |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | unavailable | unavailable | — |
| Current ratio · Balance sheet | 1.6x | 63 (on a fixed band) | 9% |
| P/E (TTM) · Valuation | 111.3x | 0 (vs peers) | 23% |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | 20.0% | 100 (on a fixed band) | 18% |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet· partial63/100 · 1/3 factors with a value
- Growth· partialunavailable · 0/2 factors with a value
- Quality45/100 · 3/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation44/100 · 2/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
MEKO AB (MEKO.ST). Latest full fiscal year: 2025; data up to 2025-12-31.
Figures computed from the financial statements: revenue 18.0 bn SEK in 2025; YoY growth -0.2%; net margin 0.2%; ROE 0.6%.
The estimated value range is 24.22–34.55 SEK per share (median of 2 methods, agreement: low); assumptions are illustrative. Against the central value of 28.65 SEK, the price of 71.20 SEK leaves a potential of -59.8% (value / price − 1) and a margin of safety of -148.5% (1 − price / value). The range is the median of the methods' low, central and high values, not a probability interval.
Insufficient data for a verdict (score weight coverage: 45.8% of at least 60%).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- FCF conversion: 2,222.2%
- FCF yield: 20.0%
What contradicts it
- ROIC: 4.6%
- Net margin: 0.2%
- P/E (TTM): 111.2x
- The price is above the estimated value range
- The valuation methods diverge
Not assessed (insufficient data or a ratio without meaning): Revenue CAGR 3Y, EPS CAGR 3Y, Net debt / EBITDA, Interest coverage, EV/EBITDA, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Listed companies from Sweden · same country · compared with 39 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| ALFA.STAlfa Laval AB | 221.7 bn | 26.8 | 19.4% | 11.9% | +4.1% | +20% / +37% |
| BOL.STBoliden Ab | 146.4 bn | 15.6 | 13.3% | 10.1% | +4.8% | +15% / +86% |
| CAST.STCastellum Aktiebolag | 66.9 bn | 71.3 | 1.2% | 9.8% | −2.6% | +27% / +6% |
| AAK.STAak Ab (publ) | 47.2 bn | 13.8 | 17.2% | 7.5% | +2.2% | −31% / −15% |
| CAMX.STCamurus AB | 43.9 bn | 60.4 | 19.5% | 32.5% | +21.3% | +20% / +60% |
| BRAV.STBravida Holding AB | 29.4 bn | 23.9 | 13.7% | 4.4% | −4.9% | +80% / +118% |
| ASKER.STAsker Healthcare Group AB | 28.7 bn | 58.4 | 9.8% | 2.9% | +11.7% | −20% / unavailable |
| ALLEI.STAlleima AB | 22.9 bn | 34.1 | 4.1% | 3.6% | −5.4% | +12% / +21% |
| BURE.STBure Equity AB | 22.5 bn | — | -21.0% | — | unavailable | +19% / +19% |
| AQ.STAQ Group AB | 20.4 bn | 30.2 | 14.9% | 7.5% | +6.0% | +18% / +126% |
| ATT.STAttendo AB (publ) | 19.0 bn | 23.5 | 15.1% | 4.3% | +0.1% | +51% / +266% |
| ALTRA.STAltra Fastigheter AB | 18.8 bn | 34.7 | 3.0% | 15.1% | −2.2% | +11% / +22% |
| AFRY.STAfry Ab | 14.9 bn | 18.6 | 6.2% | 3.1% | −5.2% | −17% / +3% |
| ATRLJ-B.STAtrium Ljungberg AB | 14.0 bn | 17.0 | 2.9% | 23.9% | −2.0% | −33% / −45% |
| ACAD.STAcadeMedia AB | 13.1 bn | 15.9 | 12.7% | 4.3% | +9.7% | +26% / +145% |
| ALIG.STAlimak Group AB (publ) | 12.9 bn | 21.6 | 8.2% | 8.8% | −3.2% | −16% / +53% |
| APOTEA.STApotea AB (publ) | 11.0 bn | 48.0 | 31.3% | 3.2% | +10.1% | +18% / unavailable |
| BOOZT.STBoozt AB | 10.7 bn | 38.3 | 10.4% | 3.6% | +0.5% | +59% / +45% |
| BUFAB.STBufab AB (publ) | 5.0 bn | 9.1 | 15.1% | 6.9% | −7.4% | +35% / +108% |
| CEVI.STCellaVision AB | 4.8 bn | 31.2 | 18.0% | 20.2% | +4.9% | +21% / +13% |
| COOR.STCoor Service Management Holding AB | 4.6 bn | 18.1 | 13.0% | 2.2% | +16.7% | +1% / +24% |
| BHG.STBHG Group AB | 4.4 bn | 30.5 | 2.5% | 1.4% | +6.2% | −20% / +109% |
| ACTI.STActive Biotech AB (publ) | 4.3 bn | — | -84.5% | — | unavailable | −41% / −80% |
| MEKO.STMeko Ab | 4.0 bn | 111.3 | 0.6% | 0.2% | −0.2% | −1% / −32% |
| CARA.STCarasent AB (publ) | 1.8 bn | 51.2 | 4.1% | 10.1% | +24.9% | −9% / +86% |
1- and 3-year price returns: for MEKO.ST from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (SEK)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | 40.11 Total return -43% · Per year -43% | 71.07 Total return 1% · Per year 1% | 107.29 Total return 52% · Per year 52% |
| 3 years | 35.35 Total return -48% · Per year -20% | 70.82 Total return 2% · Per year 1% | 117.88 Total return 69% · Per year 19% |
| 5 years | 31.16 Total return -53% · Per year -14% | 70.57 Total return 4% · Per year 1% | 129.53 Total return 88% · Per year 13% |
- Exit P/E± 17.71
- Net margin± 12.39
- Annual revenue growth± 10.65
- Annual dilution± 1.04
AI analysis
The qualitative analysis has not been written for this company yet.
Products, market & competition
The qualitative analysis has not been written for this company yet.
News & filings
In the press
No news in our archive over the last 180 days.
Annual reports (ESEF)
- Annual report 202526 Oct 2026
- Annual report 202408 May 2025
Figures computed by olivLaw from ESEF annual reports and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.